Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Part of paid clinical trials in Detroit, Michigan.
- Sponsor
- Henry Ford Health System
- Study ID
- NCT05718466
- Phase
- PHASE3
- Status
- Completed
Conditions
- Recurrent or Progressive Glioblastoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUG
- Chemotherapy — DRUG
- Fractionated radiosurgery — RADIATION
Study Details
This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.
Key Dates
- First listed
- Feb 8, 2023
- Start date
- Nov 30, 2010
- Status verified
- Jun 2023
- Primary completion
- Dec 31, 2016
- Completion
- Dec 31, 2016
Study Design
- Enrollment
- 35 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Fractionated Radiosurgery and BevacizumabFRS and Bev followed by Bev combined either Irinotecan or Temozolamide or Carboplatin or Etoposide until progression
- Active Comparator: Bev with ChemoBev combined either Irinotecan or Temozolomide or Carboplatin or Etoposide until progression
Primary Outcome Measure
Local Tumor Control [ Time Frame: 2 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Henry Ford Health System | Detroit | Michigan | 48202 | - |
Find similar trials in Detroit, MI
By research site